# A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

> **NCT03563560** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Alvocidib
- **DRUG:** Cytarabine
- **DRUG:** Mitoxantrone
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicine

## Key facts

- **NCT ID:** NCT03563560
- **Lead sponsor:** Sumitomo Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563560, "A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03563560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*